UNSPSC 51162314: Acetaminophen/chlorpheniramine/phenylpropanolamine/phenyltoloxamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162314 Acetaminophen/chlorpheniramine/phenylpropanolamine/phenyltoloxamine is a Commodity code that does not reflect the work actually being solicited under it in recent state and local opportunities. The recent opportunities tagged to this code involve procurement of naloxone (an opioid antagonist) and safe drug deactivation systems, as well as multi-source generic pharmaceuticals and OTC products through cooperative purchasing — neither of which matches the combination cold and allergy medication the code name specifies. The mismatch suggests either miscoding at the source or a broader pharmaceutical-procurement intent that falls outside this specific active-ingredient commodity. Recent activity shows county health departments and multi-state cooperative purchasing alliances issuing RFPs and IFBs for pharmaceutical products, typically requiring vendors to maintain cGMP and DSCSA compliance, establish relationships with authorized wholesalers, and deliver through fixed-fee or competitive-pricing structures.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Neither solicitation identifies explicit set-aside designations. The code shows narrow recent geographic spread concentrated in Florida and the Upper Midwest multi-state cooperative system, with limited visibility into whether activity extends beyond these jurisdictions.